Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy
| Autor: | Todd Florin, Gervasio A. Lamas, Cesar A. Conde, Hector Lozano |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Statin medicine.drug_class medicine.medical_treatment Angiotensin-Converting Enzyme Inhibitors Cardioversion Angiotensin Receptor Antagonists chemistry.chemical_compound Physiology (medical) Internal medicine Atrial Fibrillation Renin–angiotensin system medicine Humans Pharmacologic therapy cardiovascular diseases Mineralocorticoid Receptor Antagonists Clinical Trials as Topic Aldosterone business.industry Rate control Atrial fibrillation medicine.disease Clinical Practice chemistry cardiovascular system Cardiology Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents Forecasting |
| Zdroj: | Heart Rhythm. 2:1000-1007 |
| ISSN: | 1547-5271 |
| DOI: | 10.1016/j.hrthm.2005.05.020 |
| Popis: | Atrial fibrillation is one of the most frequent heart rhythm disturbances found in clinical practice. Anticoagulation, rate control, cardioversion, and ablative procedures have been the mainstay of treatment. The frequent recurrence of atrial fibrillation and the side effects when antiarrhythmic drugs are used have led to dissatisfaction with available treatment of this arrhythmia. Pharmacologic therapy with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins, and perhaps aldosterone and calcium channel blockers may have a role in the prevention of atrial fibrillation onset and recurrence. We summarize the possible biologic mechanisms and the clinical observations supporting the use of non-antiarrhythmic medications in the prevention of atrial fibrillation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|